Cullinan Oncology, Inc.
NASDAQ:CGEM
11.6 (USD) • At close December 20, 2024
Overview | Financials
Numbers are in millions (except for per share data and ratios) USD.
| 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | |
|---|---|---|---|---|---|---|
| Revenue
| 0 | 0 | 18.943 | 0 | 0 | 0 |
| Cost of Revenue
| 0.31 | 0.093 | 0.053 | 0.062 | 0.07 | 0.043 |
| Gross Profit
| -0.31 | -0.093 | 18.89 | -0.062 | -0.07 | -0.043 |
| Gross Profit Ratio
| 0 | 0 | 0.997 | 0 | 0 | 0 |
| Reseach & Development Expenses
| 148.156 | 91.948 | 57.751 | 43.211 | 16.788 | 9.584 |
| General & Administrative Expenses
| 42.493 | 40.189 | 29.146 | 17.124 | 5.482 | 5.002 |
| Selling & Marketing Expenses
| 0 | 0 | 0 | 0 | 0 | 0 |
| SG&A
| 42.493 | 40.189 | 29.146 | 17.124 | 5.482 | 5.002 |
| Other Expenses
| 0.44 | 0.057 | -0.008 | -0.011 | -0.004 | 0 |
| Operating Expenses
| 191.089 | 132.137 | 86.897 | 60.335 | 22.27 | 14.586 |
| Operating Income
| -191.089 | 144.648 | -67.954 | -60.335 | -22.27 | -14.586 |
| Operating Income Ratio
| 0 | 0 | -3.587 | 0 | 0 | 0 |
| Total Other Income Expenses Net
| 21.866 | 6.668 | 0.469 | 0.877 | 0.616 | 0.397 |
| Income Before Tax
| -169.223 | 151.316 | -67.485 | -59.458 | -21.654 | -14.189 |
| Income Before Tax Ratio
| 0 | 0 | -3.563 | 0 | 0 | 0 |
| Income Tax Expense
| -14.122 | 42.121 | -2.445 | -8.609 | -1.617 | 0.397 |
| Net Income
| -153.162 | 111.214 | -65.04 | -50.849 | -20.037 | -14.189 |
| Net Income Ratio
| 0 | 0 | -3.433 | 0 | 0 | 0 |
| EPS
| -3.69 | 2.46 | -1.47 | -1.17 | -0.46 | -1.24 |
| EPS Diluted
| -3.69 | 2.38 | -1.47 | -1.17 | -0.46 | -1.24 |
| EBITDA
| -190.339 | 151.409 | -67.901 | -60.273 | -22.2 | -14.543 |
| EBITDA Ratio
| 0 | 0 | -3.587 | 0 | 0 | 0 |